Virginia Commonwealth University researchers have developed a unique anti-sickling agent that may one day be effective in treating sickle cell disease, a painful and debilitating genetic blood disorder that affects approximately 80,000 Americans.
The research team led by Donald Abraham, Ph.D., of Biological and Medicinal Chemistry, in the Department of Medicinal Chemistry in VCU's School of Pharmacy, has shown that 5-HMF, a pure compound developed by the team, has a high affinity for sickle cell hemoglobin and holds promise for the treatment of sickle cell disease.
"Our findings suggest that this anti-sickling agent may lead to new drug treatments and may one day help those suffering with sickle cell disease. This molecule, 5-HMF, is the most promising molecule to treat sickle cell anemia to come from our research group in more than 30 years," said Abraham, who is also the director of the Institute of Structural Biology and Drug Discovery.
The United States Patent and Trademark Office recently issued VCU a Notice of Allowance for a patent relating to a method of treating sickle cell disease with 5-HMF compound. A Notice of Allowance is a written notification that a patent application has cleared an internal review and it has been approved for issuance.
Sickle cell disease is caused by an abnormality in the hemoglobin molecule. Normal red blood cells carrying hemoglobin are smooth, round and flexible and can travel easily throughout blood vessels. However, sickle cells are stiff, abnormally shaped, red blood cells that do not flow freely through blood vessels. The sickle cells also may clot together causing a blockage to form which results in pain and potentially dangerous complications that can compromise a patient's organs.
According to Abraham, the 5-membered, heterocyclic, anti-sickling agent binds to hemoglobin to increase the oxygen affinity of both normal and sickle hemoglobin. In a patient with sickle cell disease, the binding action of 5-HMF would allow sickle cells to move more smoothly throughout the blood vessels of the body and prevent blockages from forming.
Source: Virginia Commonwealth University
Related stories:
Gaining ground on sickle cell disease
Although sickle cell disease is a single-gene disorder, its symptoms are highly variable. In a study published online July 14 by the
Proceedings of the National Academy of Sciences, scientists at Children's Hospital Boston and the Dana Farber Cancer Institute (DFCI), in collaboration with the Broad Institute of MIT and Harvard, report five gene variants that could potentially be helpful in predicting sickle cell disease severity, perhaps even leading to better treatment approaches in the future.
Researchers develop human stem cell line containing sickle cell anemia mutation
Researchers at Johns Hopkins have established a human cell-based system for studying sickle cell anemia by reprogramming somatic cells to an embryonic stem cell like state. Researchers at Johns Hopkins have established a human cell-based system for studying sickle cell anemia by reprogramming somatic cells to an embryonic stem cell like state. Publishing online in
Stem Cells on May 29, the team describes a faster and more efficient method of reprogramming cells that might speed the development of stem cell therapies.
Statistical tool could explain gene study variations
While scientists are using the human genome to associate certain genes with disease, Dr. Hongyan Xu wants to ensure they are accounting for natural variations in those genes.
Clumps of red and white blood cells may contribute to sickle cell disease
It’s long been known that patients with sickle cell disease have malformed, “sickle-shaped” red blood cells – which are normally disc-shaped – that can cause sudden painful episodes when they block small blood vessels.
Researchers discover theoretical model to predict jamming
Researchers at the UCLA Henry Samueli School of Engineering and Applied Science have come up with a theoretical model to predict when granular materials become jammed. This advancement not only broadens fundamental knowledge, it also provides new avenues to a number of practical areas that ranges from materials innovation to medicine. The study, currently available on the
Nature Physics Web site, will be published in the journal's print edition on May 1.
Blood disease protects against malaria in an unexpected way
Children with an inherited blood disorder called alpha thalassemia make unusually small red blood cells that mostly cause a mild form of anemia. Now, researchers have discovered that this disorder has a benefit—it can protect children against one of the world’s greatest killers, malaria, according to a new study.
Novel small molecule therapy shows benefit for anemic patients via hydration of red blood cells
Researchers are identifying innovative therapeutics for sickle cell anemia that focus on specific factors in the disease's progression, such as the important role of hydration of the red blood cells. According to a study prepublished online in
Blood, the official journal of the American Society of Hematology, a novel small molecule therapy called senicapoc showed efficacy in maintaining hydration of red blood cells and increasing hemoglobin levels in patients with sickle cell anemia. Sickle cell anemia affects about 70,000 Americans, and millions worldwide.
Diabetes makes it hard for blood vessels to relax
One way diabetes is bad for your blood vessels is by creating too much competition for an amino acid that helps blood vessels relax, researchers say.